SEC Form 4 · accession 0000905718-17-000493
Traws Pharma, Inc. · TRAW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
TYNDALL CAPITAL PARTNERS L P
10% Owner
Period of report
Apr 21, 2017
Accepted (ET)
Apr 24, 2017 · 6:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001130598
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 21, 2017 | A | 476,190 | $2.10 | A | 997,022 | I | See Note |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1As of April 21, 2017, Tyndall Partners, L.P., a Delaware limited partnership ("Tyndall"), held 997,022 shares of common stock, par value $0.01 per share ("Shares"), and warrants to purchase up to 390,624 Shares. Tyndall Capital Partners, L.P. is the general partner of Tyndall Capital Partners L.P. ("Tyndall Capital"), and possesses the sole power to vote and the sole power to direct the disposition of all Shares and other securities held by Tyndall. Tyndall Capital's interest in the securities reported herein is limited to the extent of its pecuniary interest in such securities, if any